JP2022547574A5 - - Google Patents
Info
- Publication number
- JP2022547574A5 JP2022547574A5 JP2022516046A JP2022516046A JP2022547574A5 JP 2022547574 A5 JP2022547574 A5 JP 2022547574A5 JP 2022516046 A JP2022516046 A JP 2022516046A JP 2022516046 A JP2022516046 A JP 2022516046A JP 2022547574 A5 JP2022547574 A5 JP 2022547574A5
- Authority
- JP
- Japan
- Prior art keywords
- spik
- sequence including
- seq
- amino acids
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025159797A JP2026012693A (ja) | 2019-09-11 | 2025-09-26 | 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899024P | 2019-09-11 | 2019-09-11 | |
| US62/899,024 | 2019-09-11 | ||
| PCT/US2020/046782 WO2021050217A1 (en) | 2019-09-11 | 2020-08-18 | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025159797A Division JP2026012693A (ja) | 2019-09-11 | 2025-09-26 | 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022547574A JP2022547574A (ja) | 2022-11-14 |
| JP2022547574A5 true JP2022547574A5 (enExample) | 2023-09-04 |
Family
ID=72243286
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516046A Pending JP2022547574A (ja) | 2019-09-11 | 2020-08-18 | 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ |
| JP2025159797A Pending JP2026012693A (ja) | 2019-09-11 | 2025-09-26 | 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025159797A Pending JP2026012693A (ja) | 2019-09-11 | 2025-09-26 | 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240043512A1 (enExample) |
| EP (1) | EP4028132A1 (enExample) |
| JP (2) | JP2022547574A (enExample) |
| KR (1) | KR20220080098A (enExample) |
| CN (1) | CN114901699A (enExample) |
| CA (1) | CA3150538A1 (enExample) |
| WO (1) | WO2021050217A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3145301A1 (en) * | 2019-07-08 | 2021-01-14 | Imcare Biotech, Llc. | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| JP3469580B2 (ja) | 1993-10-01 | 2003-11-25 | 帝国臓器製薬株式会社 | 新規なペプチド誘導体 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| JP2005511627A (ja) | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス，インコーポレーテッド | 抗ｃｄ３０抗体を使用する免疫学的疾患の治療 |
| EP1575514A2 (en) | 2002-07-31 | 2005-09-21 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| AU2008316224A1 (en) * | 2007-10-25 | 2009-04-30 | Viventia Biotechnologies Inc. | Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof |
| BRPI1012560A2 (pt) | 2009-04-01 | 2016-07-26 | Genentech Inc | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
| US20140308657A1 (en) * | 2010-12-09 | 2014-10-16 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | Serine protease inhibitor kazal antibodies |
| CN104994875B (zh) * | 2013-02-15 | 2018-10-09 | 免疫医疗公司 | 嵌合和人源化抗组蛋白抗体 |
| US10746742B2 (en) * | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| US11041017B2 (en) * | 2016-03-29 | 2021-06-22 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| CA3093295A1 (en) | 2018-03-06 | 2019-09-12 | Imcare Biotech, Llc | Serine protease inhibitor kazal (spik) compositions and methods |
| CN109678950B (zh) * | 2019-01-08 | 2022-05-10 | 灏灵赛奥（天津）生物科技有限公司 | spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品 |
| CA3145301A1 (en) * | 2019-07-08 | 2021-01-14 | Imcare Biotech, Llc. | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
-
2020
- 2020-08-18 JP JP2022516046A patent/JP2022547574A/ja active Pending
- 2020-08-18 CN CN202080071514.XA patent/CN114901699A/zh active Pending
- 2020-08-18 EP EP20762027.9A patent/EP4028132A1/en active Pending
- 2020-08-18 US US17/641,780 patent/US20240043512A1/en active Pending
- 2020-08-18 KR KR1020227011715A patent/KR20220080098A/ko active Pending
- 2020-08-18 WO PCT/US2020/046782 patent/WO2021050217A1/en not_active Ceased
- 2020-08-18 CA CA3150538A patent/CA3150538A1/en active Pending
-
2025
- 2025-09-26 JP JP2025159797A patent/JP2026012693A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2504551C2 (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| CN102421795B (zh) | 针对肌钙蛋白i的抗体及其使用方法 | |
| US10197573B2 (en) | HCV core lipid binding domain monoclonal antibodies | |
| JP4287280B2 (ja) | ＨＣＶＥ２グリコプロテインに対して向けられ、ｉｎｖｉｔｒｏ中和活性を有するヒトモノクローナル抗体Ｆａｂ断片 | |
| CN102906113B (zh) | 治疗性dll4结合蛋白 | |
| JP2007527406A5 (enExample) | ||
| FI3718564T3 (fi) | Uusia anti-IL 13 -vasta-aineita ja niiden käyttöjä | |
| JP2020516603A5 (enExample) | ||
| JP2009517057A5 (enExample) | ||
| JP2005528914A5 (enExample) | ||
| RU2007118670A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
| JP2025111457A5 (enExample) | ||
| EP3983806A1 (en) | Multiplex competition assay for profiling binding epitopes of affinity agents for clinical diagnostics use | |
| JP2023518225A5 (enExample) | ||
| JP2020189843A5 (enExample) | ||
| JP2021515597A5 (enExample) | ||
| JP2022540079A5 (enExample) | ||
| CN114650866B (zh) | 新的用于诊断的分子 | |
| JP5821198B2 (ja) | 抗ｉｌ２８ｂ抗体及びこれを用いたｉｌ２８ｂの測定方法 | |
| KR102078879B1 (ko) | 돼지파보바이러스에 특이적인 단일클론항체 및 이의 용도 | |
| WO2024093042A1 (zh) | 一种抗bsa的兔单克隆抗体及其应用 | |
| WO2022238481A1 (en) | Antibodies | |
| KR20230124280A (ko) | 메르스 코로나 바이러스의 뉴클레오캡시드 단백질에 특이적인 진단용 항체 및 이의 용도 | |
| CN115210256A (zh) | 用于前列腺癌诊断的新方法和化合物 | |
| JP2023156197A5 (enExample) |